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Background. Although antipsychotic medication is the ﬁrst line of treatment for schizophrenia, many service users
choose to refuse or discontinue their pharmacological treatment. Cognitive therapy (CT) has been shown to be
eﬀective when delivered in combination with antipsychotic medication, but has yet to be formally evaluated in its
absence. This study evaluates CT for people with psychotic disorders who have not been taking antipsychotic
medication for at least 6 months.
Method. Twenty participants with schizophrenia spectrum disorders received CT in an open trial. Our primary
outcome was psychiatric symptoms measured using the Positive and Negative Syndromes Scale (PANSS), which
was administered at baseline, 9 months (end of treatment) and 15 months (follow-up). Secondary outcomes were
dimensions of hallucinations and delusions, self-rated recovery and social functioning.
Results. T tests and Wilcoxon’s signed ranks tests revealed signiﬁcant beneﬁcial eﬀects on all primary and secondary
outcomes at end of treatment and follow-up, with the exception of self-rated recovery at end of treatment. Cohen’s
d eﬀect sizes were moderate to large [for PANSS total, d=0.85, 95% conﬁdence interval (CI) 0.32–1.35 at end of
treatment ; d=1.26, 95% CI 0.66–1.84 at follow-up]. A response rate analysis found that 35% and 50% of participants
achieved at least a 50% reduction in PANSS total scores by end of therapy and follow-up respectively. No patients
deteriorated signiﬁcantly.
Conclusions. This study provides preliminary evidence that CT is an acceptable and eﬀective treatment for people
with psychosis who choose not to take antipsychotic medication. An adequately powered randomized controlled trial
is warranted.
Received 25 March 2011 ; Revised 10 August 2011 ; Accepted 23 August 2011 ; First published online 14 September 2011
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Introduction
Although antipsychotic medication is seen as the ﬁrst
line of treatment for schizophrenia and clinical guide-
lines suggest that there are clear beneﬁts in terms of
symptom reduction (NICE, 2009), there is also evi-
dence that many service users choose to refuse or dis-
continue their pharmacological treatment. The largest
trial (Lieberman et al. 2005) to compare atypical
antipsychotics found that 74% of patients with a di-
agnosis of schizophrenia chose to discontinue their
medication over 18 months and it is estimated that
rates of medication non-compliance in schizophrenia
can be as high as 40% to 50% (Lacro et al. 2002). It is
well known that service users with psychosis are
often opposed to taking medication (Moncrieﬀ et al.
2009), which may be due to several factors, including
lack of insight, stigma and concerns about side-eﬀects
[including extrapyramidal side-eﬀects, weight gain,
sexual dysfunction, metabolic and cardiovascular
problems (Tandon et al. 2008) and an increased dose-
related risk of sudden cardiac death (Ray et al. 2009)].
There is also emerging evidence to suggest that
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antipsychotic medications may cause some of the
cerebral abnormalities that were commonly assumed
to be part of the schizophrenia syndrome (Moncrieﬀ &
Leo, 2010 ; Ho et al. 2011). Many have a poor response
to antipsychotics, which will also aﬀect decisions re-
garding medication ; for example, a meta-analysis by
Leucht et al. (2009) found that atypical antipsychotics
had, on average, only a 10-point superiority over
placebo on the Positive and Negative Syndromes Scale
(PANSS), equivalent to less than minimal improve-
ment on the Clinical Global Impressions (CGI) Scale.
Best practice guidelines have suggested that, in some
circumstances, stopping medications may be indicated
(Tam & Law, 2007). The consequences of poor ad-
herence to treatment often include greater likelihood
of hospital admission, and longer hospitalizations
(Perkins, 2002), although this may be because no
eﬀective alternative treatment options are available.
However, it is clear that many people hospitalized
with psychosis retain treatment decision-making
capacity (Owens et al. 2008). A literature review re-
garding choice and decision making in people using
mental health and social care services concluded
that ‘ the literature makes it abundantly clear that ser-
vice users want to be oﬀered more than just medi-
cation’ (Warner et al. 2006), a ﬁnding supported by
a recent meta-analysis demonstrating very low drop-
out rates (average 13%) from long-term trials of
psychosocial treatments in schizophrenia (Villeneuve
et al. 2010).
Cognitive therapy (CT) has been shown to be eﬀec-
tive when delivered in combination with antipsychotic
medication, with several meta-analyses showing ro-
bust support for this approach (e.g. Pilling et al. 2002 ;
Wykes et al. 2008), although there is not complete
consensus regarding such conclusions (Lynch et al.
2010). However, it has yet to be formally evaluated in
the absence of such medication, although there have
been a few case studies (e.g. Morrison, 1994) that have
demonstrated acceptability and provided some sup-
port. More recently, two case series have demon-
strated some beneﬁts, with four patients with auditory
hallucinations showing some gains in terms of re-
duced symptoms, distress and disability (Morrison,
2001a) and three patients with a diagnosis of schizo-
phrenia showing improvements in positive and nega-
tive symptoms (Christodoulides et al. 2008). We have
shown that CT for people at risk of developing psy-
chosis can prevent or delay onset of psychosis without
the use of antipsychotic medication (Morrison et al.
2004a). As the beneﬁts of CT for people not taking
antipsychotics are unknown, although preliminary
evidence is encouraging, guidance regarding the
development and evaluation of complex interventions
such as psychological treatments suggests that it is
appropriate to conduct a phase II or exploratory study
(MRC, 2000). This will inform the design of sub-
sequent deﬁnitive trials regarding expected treat-
ment eﬀects, identiﬁcation of appropriate outcome
measures and follow-up periods, estimates of recruit-
ment and attrition for a main trial, and acceptability
and feasibility of the intervention. This exploratory
study, therefore, aimed to conduct a preliminary
examination of the feasibility and eﬀectiveness
of CT for people with psychosis who have decided




We carried out a two-site exploratory or phase II study
(MRC, 2000) of CT to assess the feasibility and eﬀec-
tiveness of CT for people not taking antipsychotics.
Our protocol was approved by the National Research
Ethics Service of the UK’s National Health Service
(NHS) and also by local NHS ethics committees at the
trial sites.
Participants
Entry criteria for the trial included being in contact
with mental health services and either meeting ICD-10
criteria for schizophrenia, schizo-aﬀective disorder
or delusional disorder or meeting entry criteria for
an early intervention in psychosis (EIP) service
(operationally deﬁned using PANSS scores of at least 4
on hallucinations or delusions or at least 5 on concep-
tual disorganization, grandiosity or suspiciousness, in
the context of initial presentation to services with
psychotic experiences). Participants had to either have
discontinued antipsychotic medication for at least
6 months while experiencing continuing symptoms or
to have never taken antipsychotics and be currently
refusing to do so. All participants had to score at least
4 on PANSS delusions or hallucinations or at least 5
on grandiosity or suspiciousness and be aged 16–65
years. Exclusion criteria included current in-patient
admission, current receipt of antipsychotic medi-
cation, moderate to severe learning disability, organic
impairment, primary diagnosis of drug or alcohol
misuse, previous cognitive behavioural therapy (CBT)
for psychosis and being non-English speaking (as this
would prevent the use of standardized assessment
instruments). Diagnosis was established using case-
notes and a standardized checklist (ICD-10) ; all diag-
noses were reviewed by a consultant psychiatrist
(D.T.). All participants were identiﬁed by psychia-
trists, care coordinators and other relevant mental
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health staﬀ within participating mental health trusts at
our two sites (Manchester and Newcastle/North East).
Outcomes
Our primary outcome measure was the PANSS (Kay
et al. 1987), which is a clinician administered 30-item
semi-structured interview consisting of seven items as-
sessing positive symptomatology (e.g. hallucinations,
delusions, conceptual disorganization), seven items
assessing negative symptomatology (e.g. blunted af-
fect, passive/apathetic social avoidance) and 16 items
assessing general psychopathology (e.g. depression,
anxiety, lack of insight, guilt). All items are scored
between 1 (not present) and 7 (severe). Several studies
have demonstrated the reliability and validity of the
PANSS (Kay et al. 1988).
Secondary outcomes included dimensions of
psychotic experiences such as severity, distress and
disability, measured using the Psychotic Symptoms
Rating Scales (PSYRATS; Haddock et al. 1999), which
is a clinician-administered semi-structured interview
consisting of 11 items assessing dimensions of audi-
tory hallucinations and six items assessing dimensions
of delusional beliefs. All items are scored from 0 to 4,
with higher scores indicating more severe phenomena.
The items assess frequency, preoccupation, location,
loudness, conviction, amount of unpleasant content,
severity of unpleasant content, amount of distress, in-
tensity of distress, degree of impairment and control.
We also included a user-deﬁned measure of recovery,
the Questionnaire about the Process of Recovery
(QPR; Neil et al. 2009), which is a 22-item question-
naire developed collaboratively with service users,
measuring subjective recovery in two domains : in-
trapersonal functioning and interpersonal functioning.
Participants rate their agreement with statements on a
ﬁve-point Likert scale rating from ‘strongly disagree ’
to ‘strongly agree’. The subscales have good internal
consistency and test–retest reliability over short
periods. Social functioning was assessed using the
Personal and Social Performance Scale (PSP; Morosini
et al. 2000), which is a 100-point single-item rating
scale based on the assessment of patient’s functioning
in four areas (socially useful activities, personal
and social relationships, self-care and disturbing
and aggressive behaviour). Informed by accepted
thresholds of clinically signiﬁcant change in PANSS
total scores (Leucht et al. 2006, 2010), a good clinical
outcome was deﬁned a priori as a o50% improve-
ment ; a moderate outcome was deﬁned as a 25%
improvement ; and a poor clinical outcome as a 25%
deterioration. Initiation of antipsychotic medication
was also monitored using self-report at each assess-
ment interview.
The participants were assessed at 3-monthly inter-
vals for a period of 9 months (end of treatment), and
then again at 15 months (follow-up) ; PANSS was only
conducted at baseline, end of treatment and follow-up
so as to reduce participant burden. Assessments were
conducted by research assistants (M.W., H.S., S.B.),
and good inter-rater reliability was established using
ratings of videotapes of PANSS ratings (initially
and mid-way through the trial) ; this was examined
using intraclass correlations (ICCs) for ratings of
recorded interviews and was shown to be good
(ICC=0.83).
Intervention
The CT intervention was limited to a maximum of
26 sessions over 9 months and followed the principles
developed by Beck (1976). It was problem orientated,
time limited, and encouraged collaborative empiri-
cism, guided discovery and homework tasks, and
was based on a written manual. It was based on an
integrative cognitive model of hallucinations and de-
lusions (Morrison, 2001b), which emphasizes the cul-
turally unacceptable interpretations that people with
psychosis make for events, in addition to their re-
sponses to such events and their beliefs about them-
selves, other people and control strategies. The central
features of our approach to treatment of psychosis
involves normalizing the interpretations that people
make, helping them to generate and evaluate alterna-
tive explanations, decatastrophizing their fears, help-
ing them test out such appraisals using behavioural
experiments and helping them to identify and modify
unhelpful cognitive and behavioural responses. It also
incorporated metacognitive change strategies, includ-
ing postponement of perseverative processing, evalu-
ation of positive and negative metacognitive beliefs
and modiﬁcation of thought control strategies. A more
detailed analysis of the treatment strategies can be
found in our treatment manuals (Morrison et al. 2004b ;
Kingdon & Turkington, 2005), and our approach is
consistent with a recent consensus exercise regarding
essential elements of CBT for psychosis (Morrison &
Barratt, 2010).
In total, eight therapists contributed to the delivery
of CT within the trial. The number of participants
treated by each therapist ranged between one and 10.
Sites varied as follows : Manchester (three therapists) ;
North East (ﬁve therapists). Five of the therapists were
clinical psychologists, two were nurses with an ad-
ditional specialist cognitive therapy qualiﬁcation and
one was a psychiatrist. All received additional training
associated with the trial manual and received weekly
individual supervision and bimonthly peer super-
vision with all other trial therapists.
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Data analysis
Distributions of the data were inspected for normality
using visual inspection and analysis of skewness and
kurtosis ; all data were normally distributed except
PANSS positive and negative subscales and the
PSYRATS auditory hallucinations subscale. Depen-
dent t tests were used to analyse changes in outcome
measures for the normally distributed variables ; non-
parametric analyses using Wilcoxon’s signed ranks
test were used for skewed data. Tests of signiﬁcance
were two-tailed, but no correction was made for
multiple comparisons given that this was a feasibility
study in which we were less concerned about type 1
error. Treatment eﬀect sizes for changes in symp-
tom scores between pre- and post-treatment and
between pretreatment and follow-up were estimated
using Cohen’s d statistic, which was calculated as
(mean1xmean2)/(S.D.)pooled (Cohen, 1988). Clinically
signiﬁcant change was examined using thresholds of
25% and 50% improvement on adjusted PANSS total
scores (Leucht et al. 2006, 2010). Missing data were
replaced by using the last observation carried forward
(LOCF) approach; although this assumption of stab-
ility is likely to bias results when comparing two or
more treatments (Hamer & Simpson, 2009), it is argu-
ably a conservative assumption in an uncontrolled
study.
Results
We ﬁnished recruiting for the trial in October 2009 and
had a ﬁnal sample size of 20 (Manchester n=12,
Newcastle/North East n=8). The characteristics of the
sample are presented in Table 1. The CONSORT
(Consolidated Standards Of Reporting Trials) diagram
for the study is provided in Fig. 1. The participants
received a mean of 16.7 sessions (S.D.=7.26, range
1–26), each session lasting approximately 1 h. Adher-
ence to CT was acceptable, with no participant not
attending any sessions, and 19/20 receiving at least
six sessions. No adverse events were reported.
Analyses of the eﬀects of CT on our primary out-
come (PANSS), including both total score and sub-
scales, at both end of treatment and follow-up, are
shown in Table 2 ; both tests of signiﬁcance (t tests) and
eﬀect sizes (Cohen’s d) are reported. It is clear that the
dimensions of our primary outcome all demonstrated
a signiﬁcant reduction at both end of treatment and
follow-up.
Table 1. Participant characteristics
Age (years), mean (S.D.) 26.75 (11.11)
Males :females 10 :10
Duration of untreated psychosis
(months), mean (S.D.)
24.68 (25.20)
Duration of illness (months), mean (S.D.) 63.57 (48.76)
In employment education or training :NEET 9 :11










Both hallucinations and delusions 10
S.D., Standard deviation ; NEET, not in education,
employment or training.
Assessed for eligibility (n = 26)
Excluded (n = 6)
Did not meet entry criteria (n = 5)
Due to antipsychotic medication = 1
Not meeting criteria on the PANSS = 4 
Declined involvement before assessment 
complete (n = 1)
Recruited into the study (n = 20)
Allocated to CT plus monitoring (n = 20)
Received 6 or more sessions of CT (n = 19)
Did not receive 6 or more sessions of CT (n = 1)
End-of-treatment assessment
Assessed (n = 17)
Declined assessment (n = 1)
Withdrew from study (n = 2)
6-month follow-up assessment
Assessed (n = 15)
Declined assessment (n = 3)
Withdrew from study (n = 2)
Analysed (n = 20)
Excluded from analysis (n = 0)
Last observation carried forward (LOCF)
at end-of-treatment analysis (n = 3)
LOCF at follow-up analysis (n = 5)
Sites n = 2, therapists n = 8
Number allocated per therapist per site: 
Manchester (10, 1, 1), Newcastle (2, 2, 2, 1, 1) 
Fig. 1. CONSORT diagram for participant ﬂow.
CT, Cognitive therapy ; PANSS, Positive and Negative
Syndromes Scale.
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Table 3 shows the results of our secondary out-
comes at the end-of-treatment and follow-up end-
points ; again, both tests of signiﬁcance (t tests) and
eﬀect sizes (Cohen’s d) are reported. These analyses
show that dimensions of hallucinations and delusional
beliefs signiﬁcantly reduced at both end of treatment
and follow-up. They also show a signiﬁcant improve-
ment in functioning at both end of treatment and
follow-up, with a signiﬁcant increase in self-rated re-
covery at follow-up but not at end of treatment.
An analysis of levels of clinically signiﬁcant change
by consideration of percentage change in our primary
outcome of PANSS total scores (adjusted) (Leucht et al.
2010) is shown in Table 4. This shows that few par-
ticipants showed no change or deteriorated, whereas
a sizable number reported levels of change consistent
with good and very good clinical outcomes (Leucht
et al. 2006). Throughout the 9-month treatment period,
one of 20 participants commenced antipsychotic
medication (this participant had a 29% decrease at
end of treatment and a 60% decrease on PANSS total
score at follow-up). Additionally, a further two of
20 participants commenced antipsychotic medication
throughout the 9–15-month follow-up period (they
had, respectively, a 4% increase and a 0.4% decrease
at end of treatment, and a 2% decrease and 0.13%
decrease on PANSS total scores at follow-up).
Discussion
Our study has demonstrated that CT for psychosis, in
the absence of antipsychotic medication, is an accept-
able treatment and is associated with a clinically sig-
niﬁcant reduction in psychiatric symptoms at both end
of treatment and follow-up, in a group that are as-
sumed to deteriorate without total adherence to medi-
cation (Subotnik et al. 2011). We also demonstrated
that CT is associated with a meaningful reduction in








Pretreatment to post-treatment Pretreatment to follow-up
t/Wa p d 95% CI t/Wa p d 95% CI
PANSS
total
69.55 (11.99) 59.20 (19.52) 54.30 (17.23) 3.66 0.002 0.85 0.32–1.35 5.63 0.000 1.26 0.66–1.84
PANSS
positivea
18.75 (4.74) 14.65 (7.37) 13.35 (6.11) 2.99 0.003 0.87 0.45–1.53 3.31 0.001 1.08 0.51–1.62
PANSS
negativea
14.60 (5.06) 12.40 (5.58) 12.15 (5.41) 3.33 0.001 1.00 0.45–1.54 2.80 0.005 0.79 0.27–1.28
PANSS
general
36.20 (6.28) 32.15 (10.36) 28.25 (9.45) 2.15 0.045 0.48 0.04–0.97 4.86 0.000 1.09 0.52–1.63
PANSS, Positive and Negative Syndromes Scale ; S.D., standard deviation ; CI, conﬁdence interval.
a For normally distributed data, parametric tests were used. For skewed distributions non-parametric Wilcoxon tests were
used.








Pretreatment to post-treatment Pretreatment to follow-up
t/Wa p d 95% CI t/Wa p d 95% CI
PSYRATS
hallucinationsa
19.35 (15.03) 10.80 (13.34) 9.65 (12.81) 2.17 0.030 0.56 0.84–1.03 2.70 0.008 0.70 0.20–1.19
PSYRATS
delusions
14.70 (6.67) 6.45 (7.07) 6.40 (6.69) 4.41 0.000 0.99 0.44–1.52 4.31 0.000 0.98 0.42–1.15
QPR total 48.83 (15.69) 57.22 (18.59) 60.96 (18.80) 1.69 0.110 0.41 0.09–0.90 2.50 0.024 0.65 0.08–1.11
PSP total 47.4 (13.80) 56.45 (18.37) 66.05 (18.31) 2.44 0.025 0.54 0.07–1.01 3.99 0.001 0.87 0.34–1.37
PSYRATS, Psychotic Symptoms Rating Scales ; QPR, Questionnaire about the Process of Recovery ; PSP, Personal and Social
Performance Scale ; S.D., standard deviation ; CI, conﬁdence interval.
a For normally distributed data, parametric tests were used. For skewed distributions non-parametric Wilcoxon tests were
used.
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dimensions of hallucinations and delusional beliefs
over a similar time frame. CT is also associated with
improved functioning and self-rated recovery, with
signiﬁcant increases shown at follow-up for both, and
a signiﬁcant improvement in functioning also dem-
onstrated at end of treatment. Only one participant
started antipsychotic medication throughout the treat-
ment window, with an additional two commencing
during the follow-up phase, which suggests that the
observed eﬀects were not attributable to instigation of
antipsychotic medication; whether CT may facilitate
the acceptance of antipsychotic medication in people
who were previously unwilling to do so remains un-
clear without a control group comparison. The low
drop-out rate that was observed, with only two with-
drawals from the trial and all but one participant re-
ceiving at least six sessions, suggests that CT is an
acceptable intervention for people who choose not to
take antipsychotics. Our eﬀect sizes and response rates
suggest that the magnitude of change associated with
the treatment can be considered good, although as an
exploratory study these ﬁndings clearly need to be
evaluated further within a deﬁnitive trial.
Given the poor compliancewith antipsychoticmedi-
cations and also their adverse side-eﬀects proﬁles, it is
encouraging that CT seemed to be both acceptable and
of beneﬁt to patients who refuse or discontinue such
medication. These ﬁndings, together with the exten-
sive evidence base supporting CT’s eﬀectiveness for
treating co-morbid disorders such as anxiety and de-
pression, suggest that patients refusing antipsychotics
should be oﬀered CT. If replicated in a deﬁnitive
trial, such evidence may support the promotion of in-
formed choices for clinicians, service users and carers,
in which they are entitled to choose from a range of
evidence-based treatments on the basis of likely ben-
eﬁts being weighed against likely adverse eﬀects. It is
worth noting that although many participants made
clinically signiﬁcant reductions, none experienced a
clinically signiﬁcant deterioration in symptoms as
based on their PANSS scores.
This study has numerous methodological limi-
tations, as is likely to be the case for a phase II explora-
tory trial (MRC, 2000). The small sample size, which
was a convenience sample, clearly limits statistical
power ; nonetheless, we found signiﬁcant eﬀects on
all outcome measures. The sample was also diag-
nostically heterogeneous (schizophrenia spectrum
disorders), which could be viewed as a methodologi-
cal weakness ; however, given the development of
services for psychosis and the emphasis on diagnostic
uncertainty that exists within EIP services, it should
ensure that our ﬁndings are generalizable to such real-
world settings such as the NHS. The use of LOCF to
deal with missing data is open to criticism (Hamer &
Simpson, 2009) ; however, we had a low proportion of
such missing data and given that this was an open trial
with a single arm, it represents a conservative ap-
proach to the analysis of treatment eﬀects. Alternative
approaches to handling missing data, such as mixed
models, which estimate parameters and test hypoth-
eses about them but do not impute missing values,
are viewed as preferable when sample sizes are large
because they allow the use of sensitivity analysis to
investigate diﬀerent assumptions (Hamer & Simpson,
2009). However, as they rely on theory that only ap-
plies to large samples, they would be inappropriate for
this study. Treatment ﬁdelity was not formally as-
sessed, but the supervision and training of therapists
should have ensured a consistent approach to delivery
of CT within the study, given that both sites have es-
tablished expertise in this approach and include the
authors of our published treatment manuals ; the in-
itial training included establishing consensus regard-
ing a list of permitted intervention strategies and some
agreed milestones (such as early establishment of
problem/goals lists and a maintenance formulation).
It is also possible that there may be therapist or site
eﬀects ; however, given the small sample size and early
phase of the trial, such analyses would not be appro-
priate here. Perhaps most signiﬁcantly, the fact that
this was an open trial clearly suggests the possibility
of bias resulting from allegiance eﬀects and non-blind
ratings. Similarly, the lack of a control condition is
problematic. All of these methodological limitations
are likely to lead to inﬂated estimates of treatment
eﬀects, as CBT for psychosis trials that attempt mask-
ing were reported to be associated with a reduction of

















Pretreatment–post-treatment 20 3 7 3 5 2
Pretreatment–follow-up 20 2 7 1 6 4
PANSS, Positive and Negative Syndromes Scale.
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eﬀect sizes of nearly 60% (Wykes et al. 2008). There-
fore, a randomized controlled trial (RCT) evaluating
CT for people with psychosis not taking antipsychotics
is required to examine the eﬀectiveness using more
robust methodology. Based on the ﬁndings from this
exploratory trial, we are currently conducting a two-
site RCT (the ACTION trial, ISRCTN 29607432) that
uses independent, random allocation, a control con-
dition, masking and examination of the sensitivities of
treatment eﬀect estimates to missing outcome data
arising from patient drop-out in addition to site or
therapist eﬀects.
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